Antoni Chan MD (Prof)
Tweet
In the phase 2a AFFINITY study of 91 patients with PsA and inadequate response to TNF inhibition, guselkumab plus golimumab reduced the TNF activity score, CRP and IL6, while guselkumab alone showed numerical reductions only. Responders to combination therapy had higher baseline https://t.co/E9gEb8sN2j
